Cell therapy (CAR-T) · Kills target cells, directed at MICA/MICB (MHC class I polypeptide-related sequences A and B), alpha 3 domain · developed by Fate Therapeutics
FT836 is an allogeneic, off-the-shelf T-cell product derived from clonal iPSCs and engineered with a chimeric antigen receptor that binds the alpha 3 domain of MICA and MICB, stress-induced NKG2D ligands expressed on many cancer cells. It also carries an alloimmune defense receptor targeting CD137 and a CD58 knockout. It is being studied in non-small cell lung, colorectal, breast, ovarian and endometrial cancers and head and neck squamous cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07216105 | Phase 1 | Non-Small Cell Lung Cancer | Recruiting | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerColorectal CancerEndometrial CarcinomaHead and Neck Squamous Cell CarcinomaNon-Small Cell Lung CancerOvarian Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →